LMBRD2: A Potential Drug Target for Various Diseases (G92255)
LMBRD2: A Potential Drug Target for Various Diseases
LMBRD2 (LMBD2_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the LAMBDA family of proteins, which are known for their role in intracellular signaling.
LMBRD2 has been shown to play a role in a variety of physiological processes in the body, including cell signaling, DNA replication, and stress response. It is also involved in the development and progression of several diseases, including cancer.
As a potential drug target, LMBRD2 has been targeted by researchers for its potential to treat a range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Researchers have found that LMBRD2 plays a role in the development and progression of these conditions, and that inhibiting its activity may be a useful therapeutic approach.
One of the main advantages of LMBRD2 as a drug target is its relatively simple structure. LMBRD2 is a protein that consists of a single polypeptide chain, which makes it relatively easy to design and develop drugs that target specific regions of the protein. This has led to a flurry of research and development efforts aimed at identifying and optimizing LMBRD2-targeting drugs.
Another advantage of LMBRD2 is its involvement in a variety of cellular processes that are important for human health and disease. For example, LMBRD2 is involved in the regulation of cell signaling, which is critical for the development and progression of many diseases. It is also involved in DNA replication, which is critical for the maintenance of genetic integrity and is important for the development and repair of tissues.
In addition to its involvement in cellular processes, LMBRD2 is also involved in the development and progression of several diseases. For example, LMBRD2 has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.
Given its involvement in a variety of cellular processes and its involvement in the development and progression of diseases, LMBRD2 has generated a lot of interest among researchers as a potential drug target. Researchers have been actively searching for LMBRD2-targeting drugs that can be used to treat a range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.
While there is still much work to be done before LMBRD2 can be fully targeted as a drug, researchers are making progress in understanding its role in disease and developing LMBRD2-targeting drugs that can be used to treat a range of conditions. As the field of pharmacology continues to evolve, it is likely that the development of LMBRD2-targeting drugs will become increasingly important for the treatment of a wide range of diseases.
Overall, LMBRD2 is a protein that has the potential to be a valuable drug target for a variety of diseases. Its relatively simple structure and involvement in a variety of cellular processes make it an attractive target for drug developers, and its involvement in the development and progression of several diseases makes it a promising target for the treatment of a wide range of conditions. Further research is needed to fully understand the role of LMBRD2 in disease and to develop effective LMBRD2-targeting drugs.
Protein Name: LMBR1 Domain Containing 2
Functions: Recruited to ligand-activated beta-2 adrenergic receptor/ADRB2, it negatively regulates the adrenergic receptor signaling pathway (PubMed:28388415). May also regulate other G-protein coupled receptors including type-1 angiotensin II receptor/AGTR1 (Probable)
The "LMBRD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMBRD2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496
